Summary
Eagle Pharmaceuticals Inc (Eagle Pharma) is a provider of pharmaceutical injectables. The company’s commercial product portfolio includes Ryanodex for exertional heatstroke; Argatroban for thrombosis; diclofenac sodium misoprostol forosteoarthritis for rheumatoid arthritis; and docetaxel injection for oncology. Eagle pharma’s product pipeline encompasses investigational candidates such as Bendamustine RTD for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma; Bivalirudin for percutaneous transluminal angioplasty; and Pemetrexed for locally advanced or metastatic non-small cell lung cancer and mesothelioma. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in New Jersey, the US.
Eagle Pharmaceuticals Inc (EGRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eagle Pharma Secures US$12.35 Million In Venture Financing 11
Partnerships 11
Eagle Pharma Enters into Agreement with National Institutes of Health 11
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 12
Arsia Therapeutics Enters into Research Agreement with Biogen 13
Eagle Pharma Enters into Agreement with Spectrum Pharma 14
Licensing Agreements 15
Eagle Pharma Enters into Licensing Agreement with Teikoku Pharma 15
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 15
Eagle Pharma Enters Into Licensing Agreement With Flamel Technologies 17
Equity Offering 18
Eagle Pharma Raises USD54.3 Million in Public Offering of Shares 18
Eagle Pharma Completes IPO For US$50.3 Million 19
Asset Transactions 20
Eagle Pharma Divests Diclofenac for USD18 Million 20
Acquisition 20
Eagle Pharma to Acquire Arsia Therapeutics for up to USD78 Million 20
Eagle Pharmaceuticals Inc - Key Competitors 22
Key Employees 23
Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
May 08, 2017: Eagle Pharmaceuticals Reports First Quarter 2017 Results 25
Mar 01, 2017: Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 27
Nov 09, 2016: Eagle Pharmaceuticals Reports Third Quarter 2016 Results 30
Aug 09, 2016: Eagle Pharmaceuticals Reports Second Quarter 2016 Results 32
May 09, 2016: Eagle Pharmaceuticals Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share 34
Feb 25, 2016: Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results 36
Corporate Communications 38
May 15, 2017: Eagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer 38
Mar 16, 2017: Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors 39
Dec 19, 2016: Eagle Pharmaceuticals Announces David Pernock as President and Chief Commercial Officer 40
Jul 05, 2016: Eagle Pharmaceuticals Announces Changes to Its Board of Directors; Director, Michael Graves Appointed Chairman 41
Product News 43
Dec 13, 2016: Eagle Pharmaceuticals Reports Positive Results from Pivotal Animal Study Supporting the Efficacy of RYANODEX for Exertional Heat Stroke 43
Aug 09, 2016: Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission 45
Product Approvals 47
Mar 27, 2017: FDA Grants Priority Review for Eagle Pharmaceuticals Ryanodex NDA for the Treatment of Exertional Heat Stroke 47
Jan 23, 2017: Eagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA 48
Nov 11, 2016: Eagle Pharmaceuticals Initiates Rolling Submission of NDA for Ryanodex in Exertional Heat Stroke 49
Clinical Trials 50
Oct 31, 2016: Eagle Pharmaceuticals Announces Positive Initial Results of Animal Study Exploring Use of Ryanodex in MDMA (Ecstasy) Induced Hyperthermia Conducted at the National Institutes of Health 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Eagle Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eagle Pharma Secures US$12.35 Million In Venture Financing 11
Eagle Pharma Enters into Agreement with National Institutes of Health 11
Eagle Pharma Enters into Co-Development Agreement with Albany Molecular Research 12
Arsia Therapeutics Enters into Research Agreement with Biogen 13
Eagle Pharma Enters into Agreement with Spectrum Pharma 14
Eagle Pharma Enters into Licensing Agreement with Teikoku Pharma 15
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 15
Eagle Pharma Enters Into Licensing Agreement With Flamel Technologies 17
Eagle Pharma Raises USD54.3 Million in Public Offering of Shares 18
Eagle Pharma Completes IPO For US$50.3 Million 19
Eagle Pharma Divests Diclofenac for USD18 Million 20
Eagle Pharma to Acquire Arsia Therapeutics for up to USD78 Million 20
Eagle Pharmaceuticals Inc, Key Competitors 22
Eagle Pharmaceuticals Inc, Key Employees 23
Eagle Pharmaceuticals Inc, Subsidiaries 24List of Figures
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Eagle Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
